drugset / Trial / NCT06204107

A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

NCT06204107

Phase 1 Completed 28 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This is a randomized, open-label, single dose, crossover, phase Ⅰ trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-379 in healthy volunteers

Timeline

Start
2023-11-21
Primary completion
2023-12-06
Completion
2023-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule Oral
Subject Metformin Small molecule Oral
Subject Sitagliptin Small molecule Oral